help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asakawa, H.
Right arrow Articles by Monden, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asakawa, H.
Right arrow Articles by Monden, M.

Journal of Clinical Endocrinology & Metabolism, Vol 81, 3547-3552, Copyright © 1996 by Endocrine Society


ARTICLES

Establishment of anaplastic thyroid carcinoma cell lines useful for analysis of chemosensitivity and carcinogenesis

H Asakawa, T Kobayashi, Y Komoike, T Yanagawa, M Takahashi, E Wakasugi, H Maruyama, Y Tamaki, Y Matsuzawa and M Monden
Second Department of Internal Medicine, Osaka University Medical School, Japan.

Anaplastic thyroid carcinoma (ATC) is usually associated with a poor prognosis, with most patients dying within a few months. The mechanism of its carcinogenesis is unclear, and its rapid growth and spread often prevent effective surgical therapy. Thus, chemotherapy is necessary. However, ATC is often resistant to anticancer drugs. Therefore, prediction of chemosensitivity is important in selecting appropriate treatment. In this study, after the establishment of three cell lines (K119, KOA2, and IAA) from patients with ATC, we analyzed them for abnormalities in certain oncogenes (myc, ras, ret, and c-erbB2) and the p53 tumor suppressor gene. Only one of three cell lines (KOA2) had a N- ras mutation [codon 61 CAA(Gln)-->CGA(Arg)] and a p53 gene mutation [exon 6 codon 192 Caa(Gln)-->TAG(stop)]. We also investigated their in vitro drug sensitivity and compared it with clinical chemosensitivity, retrospectively. In vitro drug sensitivity was determined using an adhesive tumor cell culture system. Only the K119 cells were sensitive to adriamycin and cisplatin in vitro. The other two were resistant to them in vitro. These results paralleled the clinical responses. We also evaluated the in vitro drug sensitivity of a poorly differentiated thyroid carcinoma cell line (SMP) and papillary thyroid carcinoma cell lines (NPA). None of the five cell lines expressed the multidrug resistance gene (mdr-1). In conclusion, we established ATC cell lines that are suitable models for characterizing the nature of multidrug resistance and carcinogenesis.


This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
A. J. Robinson-White, H.-P. Hsiao, W. W. Leitner, E. Greene, A. Bauer, N. L. Krett, M. Nesterova, and C. A. Stratakis
Protein Kinase A-Independent Inhibition of Proliferation and Induction of Apoptosis in Human Thyroid Cancer Cells by 8-Cl-Adenosine
J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 1020 - 1029.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. Kurebayashi, K. Tanaka, T. Otsuki, T. Moriya, H. Kunisue, M. Uno, and H. Sonoo
All-Trans-Retinoic Acid Modulates Expression Levels of Thyroglobulin and Cytokines in a New Human Poorly Differentiated Papillary Thyroid Carcinoma Cell Line, KTC-1
J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2889 - 2896.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Narimatsu, Y. Nagayama, K. Akino, M. Yasuda, T. Yamamoto, T.-t. Yang, A. Ohtsuru, H. Namba, S. Yamashita, H. Ayabe, et al.
Therapeutic Usefulness of Wild-Type p53 Gene Introduction in a p53-Null Anaplastic Thyroid Carcinoma Cell Line
J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3668 - 3672.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society